

TLR8 agonist 2 Biochemical | TLR8 biochemical

TLR8 agonist 2

CATALOG #
AAA228413


PRODUCT SYNONYMS

TLR8 agonist 2; TLR8 biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	2412937-64-3
Targets&IC50	TLR8:3 nM (EC50), TLR7:33.33 uM (EC50)
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	The pharmacokinetic related parameters of TLR8 agonist 2 (Example 1) in mice administered with the intravenous administration of 1 mg/kg and the oral administration of 5 mg/kg are detected. The T 1/2 of TLR8 agonist 2 are 0.25 h (1 mg/kg i.v.) and 0.5 h (5 mg/kg p.o.), the AUC last are 450 ng/mL/hr (i.v.) and 624 ng/mL/hr (p.o.). And for oral administration, the bioavailability (%F) is 27.7%[1]
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
Transcriptional Intermediary Factor 2 (TIF2)(740-753), CAS 359821-54-8



Structure
Transcriptional Intermediary Factor 2 (TIF2)(740-753), CAS 359821-54-8

ADDITIONAL INFORMATION

Related Product Information for TLR8 biochemical	TLR8 agonist 2 is a potent and selective TLR8 agonist with an EC 50 of 3 nM for human TLR8. TLR8 agonist 2 shows less active against human TLR7 (EC 50 of 33.33 uM).
References	1. Linlin Xu, et al. Rational discovery of novel type-III FTF antagonists to competitively suppress TIF-2 coactivation in liver cancer. J Recept Signal Transduct Res. 2019 Aug;39(4):304-311.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

